Form 4: Nanophase Technologies Corp. Executive Kevin Cureton Reports Stock Option Grant
SEC Form 4 Filing
Chief Operating Officer of Nanophase Technologies, Kevin Cureton, reports the acquisition of 22,500 stock options at $2.44 per share.
Summary
- Kevin Cureton, Chief Operating Officer of Nanophase Technologies Corp., has reported a transaction involving the acquisition of 22,500 stock options.
- These options were granted at an exercise price of $2.44 per share.
- The options vest in three equal annual installments starting on December 31, 2025, and expire on December 31, 2031.
- This transaction was part of the company's annual equity compensation practices.
- The report was filed late due to an administrative error by the company.
Sentiment
Score: 6
Explanation: The document reports a routine stock option grant, which is generally neutral. However, the late filing due to an administrative error slightly lowers the sentiment.
Positives
- The stock option grant aligns executive interests with shareholder value.
- The vesting schedule encourages long-term commitment from the executive.
Negatives
- The report was filed late due to an administrative error, which could raise concerns about internal controls.
Risks
- The late filing of the report could indicate potential issues with internal compliance procedures.
- The value of the options is dependent on the future performance of the company's stock price.
Future Outlook
The vesting of the options is tied to future dates, suggesting a long-term incentive for the executive.
Management Comments
- Mr. Cureton received this grant of stock options as part of the Company's annual equity compensation practices.
Industry Context
Stock option grants are a common practice in the technology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the technology sector.
- The vesting schedule of three equal annual installments is a typical structure for such grants.
- The exercise price of $2.44 is specific to Nanophase Technologies and its current stock valuation.
Stakeholder Impact
- The stock option grant could positively impact shareholders by aligning executive interests with company performance.
- The grant provides an incentive for the executive to contribute to the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 02/23/2017 | Start date for vesting of options with an exercise price of $0.42. |
| 02/21/2018 | Start date for vesting of options with an exercise price of $0.68. |
| 05/23/2019 | Start date for vesting of options with an exercise price of $0.82. |
| 05/22/2020 | Start date for vesting of options with an exercise price of $0.51. |
| 06/18/2021 | Start date for vesting of options with an exercise price of $0.45. |
| 12/28/2022 | Start date for vesting of options with an exercise price of $4.17. |
| 12/20/2023 | Start date for vesting of options with an exercise price of $1.165. |
| 12/27/2024 | Start date for vesting of options with an exercise price of $0.61. |
| 12/31/2024 | Date of the reported stock option grant to Kevin Cureton at $2.44 per share. |
| 12/31/2025 | Start date for vesting of the newly granted options. |
| 01/13/2025 | Date the report was signed. |
Keywords
stock options, equity compensation, executive compensation, Form 4, Nanophase Technologies, insider trading, securities, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.